

# Lucia Brodosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6097479/publications.pdf>

Version: 2024-02-01

25  
papers

820  
citations

566801

15  
h-index

642321

23  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term weight loss maintenance for obesity: a multidisciplinary approach. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, 9, 37.	1.1	177
2	Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease. <i>Clinical Nutrition</i> , 2021, 40, 1330-1337.	2.3	103
3	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021, 372, m4747.	3.0	99
4	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018, 69, 1155-1163.	1.8	80
5	Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?. <i>Liver Transplantation</i> , 2010, 16, 964-973.	1.3	50
6	Virus-Specific Immune Response in HBeAg-Negative Chronic Hepatitis B: Relationship with Clinical Profile and HBsAg Serum Levels. <i>PLoS ONE</i> , 2013, 8, e65327.	1.1	36
7	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. <i>Digestive Diseases</i> , 2016, 34, 3-10.	0.8	29
8	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019, 11, 3048.	1.7	29
9	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. <i>Nutrients</i> , 2021, 13, 2748.	1.7	28
10	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. <i>Liver International</i> , 2021, 41, 731-742.	1.9	27
11	Bone marrow derived stem cells for the treatment of end-stage liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 9098-105.	1.4	27
12	ÂNASH: A glance at the landscape of pharmacological treatment. <i>Annals of Hepatology</i> , 2016, 15, 673-81.	0.6	23
13	Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial. <i>Digestive and Liver Disease</i> , 2015, 47, 1059-1066.	0.4	22
14	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score &lt;18. <i>Liver International</i> , 2015, 35, 184-191.	1.9	17
15	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 127-135.	1.4	17
16	The Effect of Liraglutide on Î²-Blockade for Preventing Variceal Bleeding: A Case Series. <i>Annals of Internal Medicine</i> , 2020, 173, 404-405.	2.0	13
17	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <i>Transplantation</i> , 2022, 106, 462-478.	0.5	13
18	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. <i>Current Pharmaceutical Design</i> , 2020, 26, 1110-1118.	0.9	9

#	ARTICLE	IF	CITATIONS
19	NEUROD1 mutation in an Italian patient with maturity onset diabetes of the young 6: a case report. BMC Endocrine Disorders, 2021, 21, 202.	0.9	8
20	Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. World Journal of Gastroenterology, 2015, 21, 3912.	1.4	6
21	Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. Annals of Hepatology, 2014, 13, 293-296.	0.6	3
22	Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 977-983.	1.1	3
23	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. Italian Journal of Medicine, 2011, 5, 82-89.	0.2	1
24	Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opinion on Pharmacotherapy, 2022, 23, 149-153.	0.9	0
25	Obesity and NAFLD: Same Problem?. , 2020, , 1-14.		0